Herbst RS, Majem M, Barlesi F, Carcereny E, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or
in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage
III Non-Small-Cell Lung Cancer. J Clin Oncol 2022 Apr 22:JCO2200227. doi: 10.1200/JCO.22.00227.
PMID: 35452273